ImmuCell (ICCC) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
13 Nov, 2026Market opportunity
Scours affects ~5 million U.S. calves annually and carries an estimated $800M–$1B yearly economic burden; it accounts for 30–40% of pre-weaning mortality in many production systems.
U.S. spending on scours preventatives reached $93M in 2025, up 14%; the presentation estimates a ~$200M U.S. TAM and a $1.4B global TAM across 20 markets.
In 2025, 55% of U.S. calves were untreated; calves using scours preventatives increased 10.4% since 2021 while total calf numbers declined 1.5%.
Rising calf values are strengthening the incentive to invest in calf health; newborn calf prices showed a 4–7x increase since 2024.
First Defense products and positioning
First Defense delivers targeted antibodies against E. coli, coronavirus and rotavirus, using a proprietary process to hyperimmunize cows and harvest colostrum antibodies.
Challenge trials reported 100% survival in a coronavirus challenge and 90% survival in an E. coli challenge; Tri-Shield plus colostrum provided 93% protection against severe rotavirus diarrhea.
First Defense neutralizing antibody levels were 3.3x–5.6x a market-leading competitor; hyperimmunized colostrum provides >2x the bioactive content of regular colostrum.
The portfolio targets distinct customer needs: Tri-Shield at $15/dose, Dual-Force at $8–$10.50/dose and First Defense Technology powder at $6.50/dose, based on average 2025 end-customer pricing.
U.S. category-spend share reached 34.1% YTD Jan–Sep 2026, versus 23.8% in 2021; treated-animal share was 17.0% YTD 2026.
Growth and manufacturing
First Defense production increased 73% from 2023 to 2026 YTD; 2026 priorities include better planning, less waste, higher utilization and optimized colostrum use.
An $8M capacity expansion includes $3.5M for freeze drying, expected complete H1 2027, and $4.5M for colostrum processing, expected complete H2 2027; investments are expected to triple capacity and cut production timelines to under one month.
Growth plans emphasize broader U.S. outreach, expansion into selected international markets and targeted product innovation; two U.S. sales hires since June 2026 increased customer reach by 60%.
International regulatory projects have started in target countries; the global opportunity is estimated at $1.4B across 20 markets.
Latest events from ImmuCell
- First Defense® growth drove 46% Q3 sales growth as profitability and capacity expanded.ICCC
Q3 2026 - Strong growth, market share gains, and financial recovery position First Defense® for expansion.ICCC
Investor presentation - Q2 2026 net income jumped to $1.8M on 11.5% sales growth and a $2M legal settlement.ICCC
Q2 2026 - Record sales and margin growth position First Defense® for continued market share gains.ICCC
Investor presentation - All proposals passed and a major manufacturing expansion was announced to support growth.ICCC
AGM 2026 - First Defense® gains share in a growing market, fueling record sales and margin expansion.ICCC
Investor presentation - Record Q1 2026 sales and net income growth fueled by margin gains and strong cash flow.ICCC
Q1 2026 - Full-year sales up 4.3% as Tri-Shield® growth and First Defense® focus offset declines.ICCC
Q4 2025 TU - Record Q1 sales, margin gains, and net income highlight strong growth and operational recovery.ICCC
Q1 2025